| Gene symbol | CISH | Synonyms | BACTS2, CIS, CIS-1, G18, SOCS | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3p21.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PertOrg | ||||
| Description | cytokine inducible SH2 containing protein | ||||
| GTO ID | GTC2376 |
| Trial ID | NCT04426669 |
| Disease | Gastrointestinal Cancer | Colo-Rectal Cancer | Pancreatic Cancer | Gallbladder Cancer | Colon Cancer | Esophageal Cancer | Stomach Cancer |
| Altered gene | CISH |
| Therapeutic/Target gene | Target gene |
| Therapy | Gene editing |
| Treatment | CISH inactivated TIL |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System |
| Year | 2020 |
| Country | United States |
| Company sponsor | Intima Bioscience, Inc. |
| Other ID(s) | 2019LS002 |
| Cohort 1 | |||||||||||
|
|||||||||||